Chizuru Saito
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chizuru Saito has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Akiyoshi Takami
Department of Hematology, Aichi Medical University, Nagakute, Aichi, Japan
2 shared publications - Hirohito Yamazaki
Cellular Transplantation Biology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
2 shared publications - Kohei Hosokawa
Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa,Ishikawa, Japan
2 shared publications - Naomi Sugimori
Cellular Transplantation Biology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
2 shared publications - Eriko Morishita
Department of Laboratory Sciences, College of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan
1 shared publication Kanako Mochizuki
Cellular Transplantation Biology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
1 shared publication
Latest Publications
- 18 November 2014
- Published by Wiley in European Journal of Haematology
- Vol. 95 (3) , 230-238
Increased glycosylphosphatidylinositol‐anchored protein‐deficient granulocytes define a benign subset of bone marrow failures in patients with trisomy 8
Trisomy 8 (+8), one of the most common chromosomal abnormalities found in patients with myelodysplastic syndromes (MDS), is occasionally seen in patients with otherwise typical aplastic anemia (AA). Although some studies have indicated that the presence of +8 is associated with the immune pathophysiology of bone marrow (BM) failure, its pathophysiology may be heterogeneous. We studied 53 patients (22 with AA and 31 with low‐risk MDS) with +8 for the presence of increased glycosylphosphatidylinositol‐anchored protein‐deficient (GPI‐AP−) cells, their response to immunosuppressive therapy (IST), and their prognosis. A significant increase in the percentage of GPI‐AP− cells was found in 14 (26%) of the 53 patients. Of the 26 patients who received IST, including nine with increased GPI‐AP− cells and 17 without increased GPI‐AP− cells, 14 (88% with increased GPI‐AP− cells and 41% without increased GPI‐AP− cells) improved. The overall and event‐free survival rates of the +8 patients with and without increased GPI‐AP− cells at 5 yr were 100% and 100% and 59% and 57%, respectively. Examining the peripheral blood for the presence of increased GPI‐AP− cells may thus be helpful for choosing the optimal treatment for +8 patients with AA or low‐risk MDS.
- 18 November 2014
- Published by Wiley in European Journal of Haematology
- Vol. 95 (3) , 230-238
Increased glycosylphosphatidylinositol‐anchored protein‐deficient granulocytes define a benign subset of bone marrow failures in patients with trisomy 8
Trisomy 8 (+8), one of the most common chromosomal abnormalities found in patients with myelodysplastic syndromes (MDS), is occasionally seen in patients with otherwise typical aplastic anemia (AA). Although some studies have indicated that the presence of +8 is associated with the immune pathophysiology of bone marrow (BM) failure, its pathophysiology may be heterogeneous. We studied 53 patients (22 with AA and 31 with low‐risk MDS) with +8 for the presence of increased glycosylphosphatidylinositol‐anchored protein‐deficient (GPI‐AP−) cells, their response to immunosuppressive therapy (IST), and their prognosis. A significant increase in the percentage of GPI‐AP− cells was found in 14 (26%) of the 53 patients. Of the 26 patients who received IST, including nine with increased GPI‐AP− cells and 17 without increased GPI‐AP− cells, 14 (88% with increased GPI‐AP− cells and 41% without increased GPI‐AP− cells) improved. The overall and event‐free survival rates of the +8 patients with and without increased GPI‐AP− cells at 5 yr were 100% and 100% and 59% and 57%, respectively. Examining the peripheral blood for the presence of increased GPI‐AP− cells may thus be helpful for choosing the optimal treatment for +8 patients with AA or low‐risk MDS.
- 15 August 2012
- Published by Springer Nature in International Journal of Hematology
- Vol. 96 (3) , 357-363
Late response to low-dose imatinib in patients with chronic phase chronic myeloid leukemia
Imatinib was the first BCR-ABL tyrosine kinase inhibitor to become clinically available. In this study, we retrospectively evaluated the long-term efficacy of low-dose imatinib (final maintenance dose <300 mg per day) due to intolerance, in comparison to optimal-dose imatinib (≥300 mg per day) in patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase. The Kaplan–Meier estimates of the median time to complete cytogenetic response, major molecular response, and complete molecular response were longer for 31 patients receiving low-dose imatinib (360, 1360, and 1420 days, respectively) than 74 patients receiving optimal-dose imatinib (170, 420, and 720 days, respectively). However, the differences in response shrank over time and progression-free survival were comparable between the two groups. These findings suggest that long-term treatment with low-dose imatinib is an acceptable alternative for patients with intolerance to the optimal dose.
- 15 August 2012
- Published by Springer Nature in International Journal of Hematology
- Vol. 96 (3) , 357-363
Late response to low-dose imatinib in patients with chronic phase chronic myeloid leukemia
Imatinib was the first BCR-ABL tyrosine kinase inhibitor to become clinically available. In this study, we retrospectively evaluated the long-term efficacy of low-dose imatinib (final maintenance dose <300 mg per day) due to intolerance, in comparison to optimal-dose imatinib (≥300 mg per day) in patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase. The Kaplan–Meier estimates of the median time to complete cytogenetic response, major molecular response, and complete molecular response were longer for 31 patients receiving low-dose imatinib (360, 1360, and 1420 days, respectively) than 74 patients receiving optimal-dose imatinib (170, 420, and 720 days, respectively). However, the differences in response shrank over time and progression-free survival were comparable between the two groups. These findings suggest that long-term treatment with low-dose imatinib is an acceptable alternative for patients with intolerance to the optimal dose.